Supplementary Materials

Supplementary Material for:

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

Shintaro Iwama, Alessandra De Remigis, Margaret K. Callahan, Susan F. Slovin, Jedd D. Wolchok, Patrizio Caturegli*

*Corresponding author. E-mail: pcat@jhmi.edu

Published 2 April 2014, Sci. Transl. Med. 6, 230ra45 (2014)
DOI: 10.1126/scitranslmed.3008002

This PDF file includes:

  • Fig. S1. H&E staining of liver, colon, and skin from mice injected with a CTLA-4 blocking antibody or control IgG (polyclonal hamster IgG).
  • Fig. S2. Western blotting analysis of CTLA-4 expression in control murine tissues.
  • Fig. S3. Analysis of CD3 expression in the normal human pituitary gland.
  • Fig. S4. Cell-specific expression of CTLA-4 in the human pituitary gland.
  • Fig. S5. Complement deposition in pituitary glands of C57BL/6J mice after injection of a CTLA-4 blocking antibody.
  • Fig. S6. Assessment of complement deposition in murine thyroids after injection of a CTLA-4 blocking antibody.
  • Table S1. Clinical trials using ipilimumab and reporting autoimmune hypophysitis as an irAE.
  • Table S2. Serum levels of PRL (ng/ml) in mice before and after injection of a hamster monoclonal IgG1 against CTLA-4 or a hamster polyclonal control IgG.
  • Table S3. Primary antibodies used for immunohistochemistry, immunofluorescence, Western blotting, and flow cytometry.
  • Table S4. Clinical trials using tremelimumab and reporting autoimmune hypophysitis as an irAE.
  • References (3462)

[Download PDF]